{"denoms":[{"counts":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"85"}],"units":"Participants"}],"groups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.\n\ntotal-body irradiation: Undergo TBI\n\nfludarabine phosphate: Given IV\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nperipheral blood stem cell transplantation: Undergo transplantation","id":"BG000","title":"Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)"},{"description":"Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.\n\ntotal-body irradiation: Undergo TBI\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nperipheral blood stem cell transplantation: Undergo transplantation","id":"BG001","title":"Arm II (TBI, Transplant, GVHD Prophylaxis)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"18","upperLimit":"72","value":"57"},{"groupId":"BG001","lowerLimit":"18","upperLimit":"74","value":"54.5"},{"groupId":"BG002","lowerLimit":"18","upperLimit":"74","value":"56"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"73"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"27"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"58"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"70"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"title":"Italy"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"The randomization will be stratified on institution, disease risk (indolent vs. aggressive), and prior conventional HCT and will be balanced (blocked) over time."}